A Meta-analysis of Retention in Methadone Maintenance by Dose and Dosing Strategy

Overview

Journal Am J Drug Alcohol Abuse

Publisher Informa Healthcare

Specialty Psychiatry

Date 2009 Jan 20

PMID 19152203

Citations 65

Authors

Yan-Ping Bao

Zhi-Min Liu

David H Epstein

Cun Du

Jie Shi

Lin Lu

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate, via meta-analysis, the influence of different methadone dose ranges and dosing strategies on retention rates in methadone maintenance treatment (MMT).

Methods: A systematic literature search identified 18 randomized controlled trials (RCTs) evaluating methadone dose and retention. Retention was defined as the percentage of patients remaining in treatment at a specified time point. After initial univariate analyses of retention by Pearson chi-squares, we used multilevel logistic regression to calculate summary odds ratios (ORs) and 95% confidence intervals for the effects of methadone dose (above or below 60 mg/day), flexible vs. fixed dosing strategy, and duration of follow-up.

Results: The total number of opioid-dependent participants in the 18 studies was 2831, with 1797 in MMT and 1034 receiving alternative mediations or placebo. Each variable significantly predicted retention with the other variables controlled for. Retention was greater with methadone doses > or = 60 than with doses < 60 (OR: 1.74, 95% CI: 1.43-2.11). Similarly, retention was greater with flexible-dose strategies than with fixed-dose strategies (OR: 1.72, 95% CI: 1.41-2.11).

Conclusions: Higher doses of methadone and individualization of doses are each independently associated with better retention in MMT.

Citing Articles

Factors Associated with Relapses in Alcohol and Substance Use Disorder.

Yazici A, Bardakci M Eurasian J Med. 2024; 55(1):S75-S81.

PMID: 39128053 PMC: 11075040. DOI: 10.5152/eurasianjmed.2023.23335.

Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco.

Fraser H, Stone J, Facente S, Artenie A, Patel S, Wilson E Int J Drug Policy. 2024; 131:104452.

PMID: 38910096 PMC: 7617003. DOI: 10.1016/j.drugpo.2024.104452.

Persistence in the Methadone Maintenance Program and Its Relationship with the Medication Regimen Complexity Index in Opioid-Dependent Patients.

Alvaro-Alonso E, Gomez-Alvarez M, Segovia-Tapiador B, Del-Pino-Illaconza M, Valencia J, Ryan P Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794137 PMC: 11123973. DOI: 10.3390/ph17050567.

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).

Beaumont S, Magel T, MacDonald S, Harrison S, Schechter M, Oviedo-Joekes E Subst Abuse Treat Prev Policy. 2024; 19(1):1.

PMID: 38172882 PMC: 10763140. DOI: 10.1186/s13011-023-00585-4.

Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment.

Hohmeier K, Cernasev A, Leibold C, Moore T, Schlesinger E, Arce I Explor Res Clin Soc Pharm. 2023; 12:100345.

PMID: 37876851 PMC: 10590992. DOI: 10.1016/j.rcsop.2023.100345.

References

Goldstein A, Judson B . Proceedings: Efficacy and side effects of three widely different methadone doses. Proc Natl Conf Methadone Treat. 1973; 1:21-44. View

DOLE V, Nyswander M, Kreek M . Narcotic blockade. Arch Intern Med. 1966; 118(4):304-9. View

Trafton J, Minkel J, Humphreys K . Determining effective methadone doses for individual opioid-dependent patients. PLoS Med. 2006; 3(3):e80. PMC: 1360079. DOI: 10.1371/journal.pmed.0030080. View

Strain E, Stitzer M, Liebson I, Bigelow G . Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994; 151(7):1025-30. DOI: 10.1176/ajp.151.7.1025. View

Blaney T, Craig R . Methadone maintenance. Does dose determine differences in outcome?. J Subst Abuse Treat. 1999; 16(3):221-8. DOI: 10.1016/s0740-5472(98)00031-2. View

DOLE V, NYSWANDER M . A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. JAMA. 1965; 193:646-50. DOI: 10.1001/jama.1965.03090080008002. View

DOLE V, Robinson J, Orraca J, Towns E, Searcy P, Caine E . Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969; 280(25):1372-5. DOI: 10.1056/NEJM196906192802502. View

Ling W, Charuvastra C, KAIM S, KLETT C . Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry. 1976; 33(6):709-20. DOI: 10.1001/archpsyc.1976.01770060043007. View

Thiede H, Hagan H, Murrill C . Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000; 77(3):331-45. PMC: 3456044. DOI: 10.1007/BF02386744. View

10.

Gruber V, Delucchi K, Kielstein A, Batki S . A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008; 94(1-3):199-206. PMC: 2821580. DOI: 10.1016/j.drugalcdep.2007.11.021. View

11.

. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA. 1998; 280(22):1936-43. View

12.

Strain E, Stitzer M, Liebson I, Bigelow G . Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl). 1994; 116(4):401-6. DOI: 10.1007/BF02247469. View

13.

Schmitz J, Rhoades H, Elk R, Creson D, Hussein I, Grabowski J . Medication take-home doses and contingency management. Exp Clin Psychopharmacol. 1998; 6(2):162-8. DOI: 10.1037//1064-1297.6.2.162. View

14.

Booth R, Corsi K, Mikulich-Gilbertson S . Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004; 74(2):177-85. DOI: 10.1016/j.drugalcdep.2003.12.009. View

15.

Ling W, Wesson D, Charuvastra C, KLETT C . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996; 53(5):401-7. DOI: 10.1001/archpsyc.1996.01830050035005. View

16.

Leavitt S, Shinderman M, Maxwell S, Eap C, Paris P . When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 2000; 67(5-6):404-11. View

17.

Strain E, Bigelow G, Liebson I, Stitzer M . Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999; 281(11):1000-5. DOI: 10.1001/jama.281.11.1000. View

18.

Schottenfeld R, Pakes J, Oliveto A, Ziedonis D, Kosten T . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997; 54(8):713-20. DOI: 10.1001/archpsyc.1997.01830200041006. View

19.

Pani P, Maremmani I, Pirastu R, Tagliamonte A, Gessa G . Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000; 60(1):39-50. DOI: 10.1016/s0376-8716(99)00140-4. View

20.

Del Rio M, Mino A, Perneger T . Predictors of patient retention in a newly established methadone maintenance treatment programme. Addiction. 1998; 92(10):1353-60. View